Press Release

CSD/BSE&NSE/PR/2026-2027 Date: June 22, 2026 To To Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400001 Bandra (E), Mumbai – 400051 Scrip Code: 530239 Scrip Symbol: SUVEN Dear Sir/Madam, Sub: News Release With reference to above subject, please find enclosed News Release of our company titled “Suven Life Sciences to showcase its Differentiated CNS Clinical Candidates and Partnering Strategies at BIO International Convention 2026, 22-25, June 2026, San Diego, USA ” This is for your information and record. Thanking you. Yours faithfully, For Suven Life Sciences Limited K. Sangeetha Laxmi Company Secretary Encl.: as above Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com News Release Suven Life Sciences to showcase its Differentiated CNS Clinical Candidates and Partnering Strategies at BIO International Convention 2026, 22-25, June 2026, San Diego, USA. Hyderabad, India, 22-June-2026 Suven Life Sciences Limited a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders, today announced its participation in the BIO International Convention 2026 (BIO-2026), one of the world's largest Biotechnology Partnering Conferences, taking place during June 22–25, 2026, in San Diego, USA. Suven Life Sciences will welcome the Delegates, Investors, and Potential Partners & collaborators from Big Pharma, Biotech companies to Booth # 6154, where the company will showcase its Differentiated CNS portfolio, including late-stage clinical assets targeting significant unmet medical needs in indications like Agitation in Dementia of Alzheimer's Type, Major Depressive Disorder, Narcolepsy, Cognitive Impairment associated with Parkinson's disease and other CNS disorders. The goal is to engage with global pharmaceutical and biotechnology companies to explore partnering strategies, out-licensing, and/or co-development initiatives for Suven clinical candidates through 62 pre-scheduled partnering meetings in 4 days of BIO-2026. The Suven delegation at BIO-2026 includes senior leaders from Management team and Research: Venkat Jasti, Chairman and Managing Director Ramakrishna Nirogi, President and Chief Scientific Officer. Anil Shinde, Vice President, Drug Chemistry. Pradeep Jayarajan, Vice President, Drug Biology. Vijay Benade, Associate Vice President, Drug Metabolism & Pharmacokinetics. Satish Jetta, Associate Vice President, Quality Assurance & Regulatory. “BIO-2026 offers a valuable opportunity to highlight the meaningful advancements across our clinical pipeline and connect with potential partners who share our dedication to addressing unmet needs in CNS disorders. The positive Phase 2b results for Ropanicant in major depressive disorder, promising and favaurble Phase-1 data for SUVN-I6107, continued progress of our Phase-3 programs, Masupirdine for agitation in dementia of Alzheimer's type and Samelisant (AWAKE study) for narcolepsy, underscore the depth and maturity of our portfolio. We look forward to exploring strategic partnering and collaboration opportunities that can help accelerate the development and commercialization of these assets,” said Mr. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences. Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com Suven Potifolio of Differentiated CNS clinical candidates: Ropanicant (SUVN-911): α4β2 receptor antagonist, novel, differentiated antidepressant candidate offering rapid onset of efficacy, pro-cognitive effects, and a favourable sexual side-effect profile. Phase-2b trial for the treatment of major depressive disorder (MDD) builds on promising safety and efficacy from a positive Phase-2a open label study. Positive Topline results from Phase-2b clinical Proof-of-Concept trial of Ropanicant for the treatment of Major Depressive Disorder announced on 17-June-2026. Global Phase-3 study to start in H1-2027. Masupirdine (SUVN-502): 5-HT6 Receptor antagonist, novel, differentiated, non- dopaminergic, non-sedative approach transforming Alzheimer’s agitation management, delivering dual impact on behavioral stabilization and cognition. Global Phase-3 (AWAKE study) in progress (95% enrolled) and Topline results expected in Q2-2027. Samelisant (SUVN-G3031): Designed to be non-controlled, non-stimulant H3 inverse agonist delivering wake-promoting efficacy with a differentiated safety edge, offering a cleaner drug– drug interaction and cardiovascular profile vs current standard of therapy. Global Phase- 3 study Initiated for EDS in Narcolepsy and Topline results expected in Q2-2028. Usmarapride (SUVN-D4010): 5-HT4 Receptor Partial Agonist, Novel approach for addressing cognitive disorders. Safe and well tolerated with dose dependent pharmacokinetics in Phase- 1 study. Phase-2 study is planned for potential treatment of cognitive disorders. SUVN-I6107: Muscarinic M1 true positive allosteric modulator (PAM) for the potential treatment of cognitive disorders. Demonstrated favourable pharmacokinetics, safety and tolerability profile (no cholinergic adverse events) in a recently completed Phase-1 trial. Pharmacodynamic outcome indicated enhanced alertness and information processing. Phase- 2 study in Planning. Suven owns all intellectual property rights for its assets in all major markets. For more information, please visit our website http://www.suven.com Risk Statement: Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time. Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com